Nageen Sharma
Craniosacral therapy
Faisalabad, Punjab, Pakistan
Years of experience 3

Total years in practice: 3

Published Date
November 02, 2010
Abstract Authors
Chung-Wah Cheng, Zhao-Xiang Bian, Li-Xing Zhu, Justin C Y Wu, Joseph J Y Sung
Abstract Source
Am J Gastroenterol. 2010 Nov 2. Epub 2010 Nov 2. PMID: 21045817
Abstract Affiliation
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.
Study Type
Research
Therapeutic Substances
Hemp seed
Conditions
Constipation
Therapies
Acupressure, Acupuncture, Herbal Therapy, Tai Chi, Traditional Chinese Medicine
Reference
Abstract Content
OBJECTIVES:
Functional constipation (FC) is a common clinical complaint. Despite a lack of consolidated evidence, Chinese herbal medicine (CHM) has become a popular alternative treatment for this condition. The aim of this study was to assess, with a rigidly designed study, the efficacy and safety of a CHM proprietary medicine, Hemp Seed Pill (HSP), in optimal dosage for treating FC.
METHODS:
This study comprised two parts: trial I, a dose determination study, and trial II, a placebo-controlled clinical study. In trial I, the optimal dosage of HSP was first determined from among three doses (2.5, 5.0, and 7.5?g b.i.d.). In trial II, a randomized double-blind study, the efficacy and safety of HSP for FC patients (Rome III criteria) in excessive syndrome as defined by traditional Chinese medicine (TCM) theory were compared with placebo. All participants in trials underwent a 2-week run-in, an 8-week treatment, and an 8-week follow-up. The primary end point was the responder rate for complete spontaneous bowel movement (CSBM) during treatment. Participants with a mean increase of CSBM ?1/week compared with their baselines were defined as responders. Secondary outcome measures included responder rate during follow-up, individual and global symptom assessments, and reported adverse effects (AEs).
Results:
The dose of 7.5?g b.i.d. showed better therapeutic effect than that of 2.5 and 5.0?g b.i.d. among 96 subjects (32 per arm) in trial I and was therefore selected for comparison with placeboin trial II. In trial II, 120 subjects were randomized into two arms (60 per arm). Responder rates for the HSP and placebo groups were 43.3 and 8.3% during treatment and 30.0 and 15.0% in the follow-up period, respectively (P
Get a Consultation
(650) 539-4545
Get more information via email